HT

Akoya to Report Second Quarter 2022 Financial Results on August 8th, 2022

Retrieved on: 
Tuesday, July 12, 2022
HIV disease progression rates, GLOBE, HT, Health, Biology, Nasdaq, Medical imaging, Akoya

MARLBOROUGH, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (Akoya), The Spatial Biology Company, today announced that it will release financial results for the second quarter of 2022 after the market close on Monday, August 8th, 2022.

Key Points: 
  • MARLBOROUGH, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (Akoya), The Spatial Biology Company, today announced that it will release financial results for the second quarter of 2022 after the market close on Monday, August 8th, 2022.
  • Company management will host a conference call to discuss financial results at 5:00 p.m.
  • A live and archived webcast of the event will be available on the Investors section of the Akoya website at https://investors.akoyabio.com/ .
  • As The Spatial Biology Company, Akoya Biosciences mission is to bring context to the world of biology and human health through the power of spatial phenotyping.

HEXO Corp.’s Shareholders Approve Note Transaction with Tilray Brands

Retrieved on: 
Tuesday, July 5, 2022
Cannabis, SEDAR, Molson Coors Beverage Company, HT, Competition, TSX, GLOBE, Power, Company, HTI, Toronto Stock Exchange, Mission statement, Indian stock exchange, Nasdaq, Meeting, NASDAQ, EDGAR, News, Competition Bureau, Intention, Security (finance), Note

GATINEAU, Québec, July 05, 2022 (GLOBE NEWSWIRE) -- HEXO Corp (“HEXO” or the “Company”) (TSX: HEXO; NASDAQ: HEXO) is pleased to announce that at its reconvened special meeting of shareholders held today (the "Meeting"), holders ("Shareholders") of common shares of HEXO ("Common Shares") approved the previously announced transaction (the “Note Transaction”) with Tilray Brands, Inc. (“Tilray Brands”) (Nasdaq | TSX: TLRY) and HT Investments MA LLC (“HTI”). The Meeting was originally held on June 14, 2022 and was adjourned prior to Shareholders voting on the Note Transaction in order to provide Shareholders with additional time to consider the previously announced amendments to the Note Transaction.

Key Points: 
  • GATINEAU, Qubec, July 05, 2022 (GLOBE NEWSWIRE) -- HEXO Corp (HEXO or the Company) (TSX: HEXO; NASDAQ: HEXO) is pleased to announce that at its reconvened special meeting of shareholders held today (the "Meeting"), holders ("Shareholders") of common shares of HEXO ("Common Shares") approved the previously announced transaction (the Note Transaction) with Tilray Brands, Inc. (Tilray Brands) (Nasdaq | TSX: TLRY) and HT Investments MA LLC (HTI).
  • The Meeting was originally held on June 14, 2022 and was adjourned prior to Shareholders voting on the Note Transaction in order to provide Shareholders with additional time to consider the previously announced amendments to the Note Transaction.
  • At the Meeting, Shareholders voted in favour of the ordinary resolution (the Note Amendment Resolution) to approve certain aspects of the Note Transaction, which provides for the amendment to the terms of the outstanding senior secured convertible note (the Note) originally issued by HEXO to HTI and the execution of an amended and restated Note (the Amended Note) with HTI that will be immediately thereafter assigned to Tilray Brands pursuant to the terms of an assignment and assumption agreement.
  • The Note Amendment Resolution was approved by 87.246% of the votes cast by Shareholders at the Meeting.

Akoya Biosciences to Partner with Acrivon Therapeutics for the Clinical Development of Acrivon’s Proprietary OncoSignature® Test into a Companion Diagnostic

Retrieved on: 
Tuesday, June 28, 2022
FDA, Patient, HT, PDX, AP3, Biology, Probability, HIV disease progression rates, ABS, GLOBE, Biomarker, Proteomics, Cancer, Squamous cell carcinoma, Marker beacon, Disease, Company, Eli Lilly and Company, DDR, Cdx, Partnership, Neoplasm, Technology, Survival, DNA, Nasdaq, Health, Mass spectrometry, Physician, Ovarian cancer, Medical imaging, Pharmaceutical industry, Akoya

ACR-368 has been evaluated in over 1,000 patients and has demonstrated durable monotherapy activity, including complete responses, in a proportion of patients with platinum-resistant ovarian cancer. These patients currently have no effective treatment options, and the median survival time with this disease is less than one year. In addition to ovarian cancer, ACR-368 is being evaluated as a treatment for endometrial and urothelial cancers -- two other high unmet need solid tumor types predicted by OncoSignature® to be highly sensitive to the drug. The OncoSignature® test, developed by Acrivon, will be run on Akoya’s PhenoImager solution during clinical development and, pending ACR-368 approval and commercialization, will enable physicians to identify and treat the patients most likely to respond to the therapy.

Key Points: 
  • Akoya, in partnership with Acrivon, will develop, clinically validate, and seek regulatory co-approval for the OncoSignature test, and, pending ACR-368 approval, commercialize the test as the exclusive provider of the companion diagnostic required for prescribing ACR-368.
  • We believe that Akoya is an ideal partner to develop and commercialize this next-generation companion diagnostic with their technically advanced, quantitative PhenoImager solution.
  • We look forward to working with Akoya towards bringing this companion diagnostic to patients and clinicians around the world.
  • Acrivon Predictive Precision Proteomics, AP3, is a proprietary, streamlined approach to develop patient selection tumor biopsy tests, called OncoSignature tests.

Humantelligence Named Remote Work Tech Startup of the Year

Retrieved on: 
Monday, June 27, 2022
People, Fortune 500, HT, Bank, CEO, Agtech, Emotional intelligence, AFLAC, Bank of the West, BASF, Coca-Cola, Telecommuting, Gmail, Technology, Digital health, Communication, Calendar, HR, Culture, Financial technology, Ashley Furniture Industries, Mobile wireless sensor network, Microsoft Outlook, Tech, Creativity, IOT, Collaboration, Management

MIAMI, June 27, 2022 /PRNewswire-PRWeb/ -- Humantelligence (HT), a pioneer in culture intelligence and leader in recruitment technology, won Remote Tech Breakthrough's 2022 Remote Work Tech Startup of the Year — recognizing the company's innovative recruitment, culture analytics, and team communication and collaboration technology for its ease of use, quick implementation, and ability to optimize collaboration on the spot for remote and hybrid teams.

Key Points: 
  • Humantelligence is recognized by RemoteTech Breakthrough for its innovative approach to improving team performance and optimizing collaboration on the spot for remote and hybrid teams.
  • MIAMI, June 27, 2022 /PRNewswire-PRWeb/ -- Humantelligence (HT), a pioneer in culture intelligence and leader in recruitment technology, won Remote Tech Breakthrough's 2022 Remote Work Tech Startup of the Year recognizing the company's innovative recruitment, culture analytics, and team communication and collaboration technology for its ease of use, quick implementation, and ability to optimize collaboration on the spot for remote and hybrid teams.
  • Remote Tech Breakthrough is part of the Tech Breakthrough organization, which specializes in 13 technology markets, serves more than 200 brands, and conducts market research and recognition programs in today's most competitive technology sectors, including IoT, Cybersecurity, AgTech, Mobile/Wireless, Digital Health, FinTech, HR and the Remote Work sector.
  • The mission of the Remote Tech Breakthrough Awards is to honor excellence and recognize the creativity, hard work and success of companies, technologies and products in the larger field of remote technology.

Bruker Presents High-Value Life Science, Materials Research and Applied Market Solutions at Analytica 2022

Retrieved on: 
Tuesday, June 21, 2022
Health, Other Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Olive, MALDI, ISO, Chromatography, X-ray, GxP, Lipid, Protein, Metabolomics, Corporation, 3D, Plasma, Spatial, Software, AT, Life, ATR, Solution, Technology, EDS, Compliance, CEO, NIR, Xenobiotic, TGA, Nasdaq, Food, Doctor of Philosophy, Temperature, TG, Drug development, Hertz, MPA, Olive oil, Neuroscience, Biology, Chemistry, SLM, HYPERION, Ownership, Mass spectrometry, Analysis, MALDI imaging, Multimedia, HT, PON, Quality control, Proteomics, Cancer, Research, Microscopy, Optogenetics, Acquisition, 4D, Partnership, CFR, QCL, Cell biology, IonSense, Fine chemical, Ceramic, Microscope, Camera, Medical imaging, Bruker, Analytica

Bruker Corporation (Nasdaq: BRKR) this week displays its high-value scientific instrumentation, software and integrated solutions for applications in materials and energy research, biopharmaceuticals, applied markets, as well as life science and translational research at Analytica 2022 .

Key Points: 
  • Bruker Corporation (Nasdaq: BRKR) this week displays its high-value scientific instrumentation, software and integrated solutions for applications in materials and energy research, biopharmaceuticals, applied markets, as well as life science and translational research at Analytica 2022 .
  • Bruker is committed to providing optimized technological, software, chemistry and biology solutions to enable the success of our customers.
  • Bruker launches the HYPERION II FT-IR / IR Laser Imaging Microscope as a flexible research platform, combining FT-IR microscopy with QCL IR laser imaging.
  • Brukers high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels.

Hersha Hospitality Trust to Report Second Quarter 2022 Earnings on August 3, 2022

Retrieved on: 
Monday, June 20, 2022
HT, Webcast, Security (finance), New York Stock Exchange, Annual report, Hersha Hospitality Trust, Company, Second, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, SEC, NYSE, GLOBE, Tourism

PHILADELPHIA, June 20, 2022 (GLOBE NEWSWIRE) -- Hersha Hospitality Trust (NYSE: HT) (Hersha or the Company), owner of high-quality hotels in urban gateway markets and regional resort destinations, today announced that the Company will release its financial results for the Second quarter 2022 after the market close on Wednesday, August 3, 2022.

Key Points: 
  • PHILADELPHIA, June 20, 2022 (GLOBE NEWSWIRE) -- Hersha Hospitality Trust (NYSE: HT) (Hersha or the Company), owner of high-quality hotels in urban gateway markets and regional resort destinations, today announced that the Company will release its financial results for the Second quarter 2022 after the market close on Wednesday, August 3, 2022.
  • The Company will host a conference call to discuss these results at 9:00 AM Eastern Time on Thursday, August 4, 2022.
  • A replay of the call will be available from 11:00 AM Eastern Time on Thursday, August 4, 2022, through 11:59 PM Eastern Time on Sunday, September 4, 2022.
  • Hersha Hospitality Trust (HT) is a self-advised real estate investment trust in the hospitality sector, which owns and operates high-quality hotels in urban gateway markets and regional resort destinations.

HEXO Corp.’s Shareholders Approve Standby Commitment Transaction

Retrieved on: 
Wednesday, June 15, 2022
The Meeting, Toronto Stock Exchange, HT, Circular, TSX, Investor, Mission statement, Indian stock exchange, SEDAR, Company, Molson Coors Beverage Company, Proxy, GLOBE, Cannabis, NASDAQ, Intention, Nasdaq, Power, EDGAR, Gatineau, Meeting, Security (finance)

At the Meeting, Shareholders voted in favour of the ordinary resolution (the Standby Commitment Resolution) to approve certain aspects of the Standby Agreement, pursuant to which the Investor agreed to subscribe for, and the Company agreed to issue and sell, on and subject to the terms of the Standby Agreement, up to $180 million in Common Shares of the Company (the Standby Commitment).

Key Points: 
  • At the Meeting, Shareholders voted in favour of the ordinary resolution (the Standby Commitment Resolution) to approve certain aspects of the Standby Agreement, pursuant to which the Investor agreed to subscribe for, and the Company agreed to issue and sell, on and subject to the terms of the Standby Agreement, up to $180 million in Common Shares of the Company (the Standby Commitment).
  • The Standby Commitment Resolution was approved by 87.246% of the votes cast by Shareholders at the Meeting.
  • The Company previously obtained, on May 13, 2022, conditional approval from the Toronto Stock Exchange for the Standby Commitment.
  • The Standby Commitment is expected to be available to the Company by the end of June 2022.

HEXO Reports Third Quarter 2022 Results

Retrieved on: 
Wednesday, June 15, 2022
Investment, Report of the Committee on Company Law Amendment, Tax, Mission statement, SEDAR, Molson Coors Beverage Company, Absorption, Depreciation, USD, MD, D&O, IFRS, Review, EBITDA, Policy, Intention, Competition Bureau, Lung compliance, Amend, International, Power, TSX, Health Canada, LLC, CAD, Failure, Cannabis, Competition, Risk, HT, Company, HTI, Acquisition, Transaction, EDGAR, Pharmaceutical industry, Security (finance), Online gambling, Life insurance, Consumer electronics, Note, Nasdaq, Tilray, Adjustment

GATINEAU, Quebec, June 14, 2022 (GLOBE NEWSWIRE) -- HEXO Corp (TSX: HEXO; NASDAQ: HEXO) ("HEXO" or the “Company"), a leading producer of high-quality cannabis products, today reported its financial results for the fiscal quarter ended April 30, 2022 (Q3’22). All amounts are expressed in Canadian dollars unless otherwise noted.

Key Points: 
  • The quarter over quarter Adjusted EBITDA was also impacted by the impact of the $3,673 Health Canada cannabis fee which is recognized in the third quarter each fiscal year.
  • HEXO serves the Canadian recreational market with a brand portfolio including HEXO, Redecan, UP Cannabis, Namaste Original Stash, 48North, Trail Mix, Bake Sale, REUP and Latitude brands, and the medical market in Canada, Israel and Malta.
  • The Company also serves the Colorado market through its Powered by HEXO strategy and Truss CBD USA, a joint venture with Molson-Coors.
  • With the completion of HEXO's recent acquisitions of Redecan and 48North, HEXO is a leading cannabis products company in Canada by recreational market share.

HEXO Enters Into Amending Agreements to the Transaction Agreement With Tilray Brands and the Standby Agreement With KAOS

Retrieved on: 
Tuesday, June 14, 2022
Competition Bureau, Mission statement, Power, HT, Nasdaq, Company, Competition, Date, Toronto Stock Exchange, Review, EDGAR, The Meeting, Disclosure, Assumption, HTI, Transaction, CEO, Partnership, Assignment, Cannabis, CAD, Intention, Circular, SEDAR, FOR, Proxy, Molson Coors Beverage Company, Report of the Committee on Company Law Amendment, Lung compliance, TSX, Canada Business Corporations Act, Investor, USD, D&O, Meeting, News, Telephone, Policy, Note, Growth, GLOBE, Risk, NASDAQ, TO, Online gambling, Security (finance), Life insurance, Holding company, Tilray

GATINEAU, Quebec, June 14, 2022 (GLOBE NEWSWIRE) -- HEXO Corp. (TSX: HEXO; NASDAQ: HEXO) (HEXO or the Company), a leading producer of high-quality cannabis products, today announcedthat the Company has entered into an amending agreement (the Amending Agreement) to the previously announced transaction agreement (the Transaction Agreement) with Tilray Brands, Inc. (Tilray Brands) (Nasdaq | TSX: TLRY) and HT Investments MA LLC (HTI).

Key Points: 
  • GATINEAU, Quebec, June 14, 2022 (GLOBE NEWSWIRE) -- HEXO Corp. (TSX: HEXO; NASDAQ: HEXO) (HEXO or the Company), a leading producer of high-quality cannabis products, today announcedthat the Company has entered into an amending agreement (the Amending Agreement) to the previously announced transaction agreement (the Transaction Agreement) with Tilray Brands, Inc. (Tilray Brands) (Nasdaq | TSX: TLRY) and HT Investments MA LLC (HTI).
  • Separately, the Company announced that it has also entered into an amending agreement to the previously announced equity purchase agreement (the Standby Agreement) with 2692106 Ontario Inc. (the Investor) and KAOS Capital Ltd. (KAOS).
  • The Circular Supplement will include further information regarding the Amending Agreement in order to permit shareholders to make a fully informed decision when considering the Transaction.
  • The Company is not required to pay the Investor any additional consideration in connection with these amendments to the Standby Agreement.

Tilray Brands Announces Enhancements to Accretive Strategic Transaction with HEXO

Retrieved on: 
Tuesday, June 14, 2022
Life, Convertible, Achievement, HT, Goal, Time, Company, Insurance, Purchasing, Securities Exchange Act of 1934, Securities Act of 1933, HTI, Tilray, Annual report, Forward-looking statement, CEO, Partnership, German–Soviet Commercial Agreement (1940), Investment, Nasdaq, Growth, GLOBE, Health, Acquisition, TSX, EDGAR, Globalization, SEC, Industry, Board, Drink, CAD, Patient, Communication, CPG, Security (finance), Online gambling, Management

LEAMINGTON, Ontario, June 14, 2022 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray Brands” or the “Company”) (Nasdaq | TSX: TLRY) today announced that the Company has entered into amendments to improve the terms of its previously-disclosed agreements to acquire all of the outstanding principal, plus accrued and unpaid interest, under a secured convertible note (the “HEXO Note”) issued by HEXO Corp. (“HEXO”) to HT Investments MA LLC (“HTI”). These amendments provide for, among other things, an additional discount to Tilray Brands’ purchase price as well as the reduction of the conversion price under the HEXO Note from CAD$0.85 to CAD$0.40 per share.

Key Points: 
  • As previously announced, the strategic alliance between Tilray Brands and HEXO is expected to provide several financial and commercial benefits, including:
    Substantial Synergies: the strategic alliance between Tilray Brands and HEXO is expected to deliver up to $80 million of shared cost-saving synergies within two years of the completion of the Transaction.
  • Accretion: as a result of the substantial synergies, the acquisition of the HEXO Note by Tilray Brands will be immediately accretive to the Company.
  • As consideration for Tilray Brands acquisition of the HEXO Note, Tilray Brands will pay 89.2% of the then outstanding principal balance for the HEXO Note (the Purchase Price).
  • HEXO will not receive any proceeds as a result of Tilray Brands proposed purchase of the HEXO Note from HTI.